NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Aurobindo Pharma Subsidiary Receives CDSCO Approval for Bevqolva Biosimilar
Aurobindo Pharma's wholly owned subsidiary, CuraTeQ Biologics, has received marketing authorization from the CDSCO for Bevqolva, a bevacizumab biosimilar. The drug is indicated for treating metastatic carcinoma of the colon or rectum, marking a significant entry into the oncology biosimilars market. The approval covers two vial presentations, 100 mg/4mL and 400 mg/16 mL, to be manufactured at the company's Hyderabad facility. This regulatory milestone strengthens Aurobindo's biologics portfolio and its long-term growth prospects in high-value therapeutic areas.
முக்கிய அம்சங்கள்
CuraTeQ Biologics received CDSCO Marketing Authorisation (Form CT 23) for Bevqolva (Bevacizumab Biosimilar).The biosimilar is indicated for the treatment of metastatic carcinoma of the colon or rectum.Approval includes two specific vial presentations: 100 mg/4mL and 400 mg/16 mL.Manufacturing and marketing will be conducted from CuraTeQ’s dedicated facility in Hyderabad.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive development in Aurobindo's shift toward complex biologics. Monitor the commercial rollout and potential for future international regulatory filings for this biosimilar.
Aurobindo Pharma has successfully concluded its share buyback program, extinguishing 54,23,728 equity shares as of May 15, 2026. The company repurchased these shares at a price of ₹1,475 per share via the tender offer route, representing a total capital return of ₹800 crore. As a result, the total equity base has been reduced from 58.08 crore shares to 57.54 crore shares. The promoter group's shareholding has marginally increased from 51.82% to 51.88% following the extinguishment.
முக்கிய அம்சங்கள்
Extinguished 54,23,728 fully paid-up equity shares of ₹1 face value each.Shares were bought back at a premium price of ₹1,475 per share for a total of ₹800 crore.Total issued share capital reduced from 58,08,01,623 to 57,53,77,895 equity shares.Promoter and Promoter Group holding increased slightly to 51.88% from 51.82%.The buyback was executed through the tender offer route in compliance with SEBI regulations.
👀 கவனிக்க வேண்டியவை
The reduction in the total number of shares is expected to be EPS-accretive, which is a positive signal for long-term shareholders. Investors should note the management's willingness to return surplus cash to shareholders at a significant premium to the face value.
Aurobindo Pharma Unit-VII Receives VAI Status from US FDA, Closing Inspection
Aurobindo Pharma's Unit-VII, a major oral solid dosage manufacturing facility in Jedcherla, has received an Establishment Inspection Report (EIR) from the US FDA. The facility was previously issued a Form 483 with 9 observations following an inspection conducted between January 28 and February 10, 2026. The US FDA has now classified the unit as Voluntary Action Indicated (VAI), which signifies that the inspection is officially closed. This is a positive development as it removes regulatory uncertainty and allows the facility to continue operations and seek new product approvals.
முக்கிய அம்சங்கள்
Unit-VII (Jedcherla) classified as Voluntary Action Indicated (VAI) by US FDAThe US FDA inspection was conducted from January 28 to February 10, 2026The facility had previously received a Form 483 with 9 observationsReceipt of the Establishment Inspection Report (EIR) marks the formal closure of the inspection
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive resolution to a previous regulatory overhang, clearing the path for future product approvals from this unit. Maintain a positive outlook on the stock as regulatory risks for this specific facility have subsided.
Aurobindo Pharma Subsidiary Secures Health Canada Approval for Bevqolva Biosimilar
CuraTeQ Biologics, a wholly-owned subsidiary of Aurobindo Pharma, has received a Notice of Compliance (NOC) from Health Canada for Bevqolva™, a biosimilar of Roche's Avastin. This approval allows the marketing of the bevacizumab biosimilar in 100 mg and 400 mg formulations for treating multiple cancers, including colorectal and lung cancer. The product is already commercially available in the UK and is currently under review by the European Medicines Agency. This milestone strengthens Aurobindo's presence in the regulated biologics market, with two more biosimilar applications pending in Canada.
முக்கிய அம்சங்கள்
Received Health Canada NOC for Bevqolva™ (Bevacizumab), a biosimilar to the originator drug AvastinProduct targets multiple cancer types and will be offered in 100 mg and 400 mg strengthsFollows a successful 2025 launch in the UK market after MHRA authorizationCuraTeQ has 2 additional biosimilar applications currently under review by Health CanadaOngoing review by the European Medicines Agency (EMA) provides further potential upside
👀 கவனிக்க வேண்டியவை
This approval validates Aurobindo's biosimilar capabilities and opens a new revenue stream in the Canadian market. Investors should maintain a positive outlook as the company scales its high-margin biologics portfolio.
Aurobindo Pharma to Buyback Shares Worth ₹800 Crore at ₹1,475 Per Share
Aurobindo Pharma has announced a buyback of up to 54,23,728 equity shares via the tender offer route at a price of ₹1,475 per share. The total buyback size is ₹800 crore, representing approximately 0.93% of the total outstanding equity shares. The offer is scheduled to open on April 23, 2026, and close on April 29, 2026, for shareholders who held stock as of the April 17 record date. Small shareholders have been offered a favorable entitlement ratio of 7 shares for every 61 shares held.
முக்கிய அம்சங்கள்
Buyback of 54,23,728 shares at a fixed price of ₹1,475 per share via tender routeTotal outlay of ₹800 crore represents 2.62% of consolidated net worth as of March 2025Entitlement ratio for small shareholders is 7:61; General category is 2:249Offer period is set from April 23, 2026, to April 29, 2026Settlement of bids expected to be completed by May 7, 2026
👀 கவனிக்க வேண்டியவை
Eligible shareholders should consider tendering their shares to take advantage of the ₹1,475 buyback price, especially if it remains at a premium to the market price. Small shareholders should particularly note their higher entitlement ratio for potential short-term gains.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Aurobindo Pharma Receives USFDA Approval for OTC Cough Syrup; Market Size $138 Million
Aurobindo Pharma has secured final USFDA approval for Dextromethorphan Polistirex Extended-Release Oral Suspension (OTC), a generic version of Delsym. The product targets a US market valued at approximately $138 million for the 12 months ending February 2026. Production is slated for the APL Healthcare Unit-IV facility with a commercial launch expected in Q2FY27. This milestone increases the company's total USFDA approvals to 580, reinforcing its strong position in the US generic market.
முக்கிய அம்சங்கள்
Final USFDA approval for Dextromethorphan Polistirex Extended-Release Oral Suspension (OTC) 30 mg/5 mL.Addresses an estimated US market size of $138 million based on Nielsen data for the year ending Feb 2026.Commercial launch is scheduled for Q2FY27 from the APL Healthcare Unit-IV facility.Total USFDA portfolio now comprises 580 approvals, including 557 final and 23 tentative approvals.
👀 கவனிக்க வேண்டியவை
This approval strengthens Aurobindo's US OTC pipeline and provides revenue visibility for FY27. Investors should maintain a positive outlook as the company continues to leverage its manufacturing scale to capture market share in the US generic space.
Aurobindo Pharma has received final USFDA approval for Glycerol Phenylbutyrate Oral Liquid (1.1 g/mL), a generic version of Ravicti. The product is indicated for the chronic management of patients with urea cycle disorders and will be launched immediately. The addressable market for this product is estimated at US$ 50.2 million for the twelve months ending February 2026. This approval further strengthens Aurobindo's extensive US portfolio, bringing its total USFDA ANDA approvals to 579.
முக்கிய அம்சங்கள்
Final USFDA approval received for Glycerol Phenylbutyrate Oral Liquid, 1.1 grams per mL.Estimated annual market size of US$ 50.2 million according to IQVIA MAT February 2026 data.The product will be manufactured at the company's Unit-III facility and launched immediately.Aurobindo now holds a total of 579 ANDA approvals, including 556 final and 23 tentative approvals.
👀 கவனிக்க வேண்டியவை
Investors should monitor the successful commercialization of this niche product as it contributes to the company's high-margin US generics business. The immediate launch and moderate market size provide a steady incremental revenue stream for the company.
Aurobindo Pharma Subsidiary to Invest $150-175M for 60KL Biologics Facility for MSD
Aurobindo Pharma's subsidiary, TheraNym Biologics, has expanded its contract manufacturing (CMO) agreement with Merck Sharp & Dohme (MSD) Singapore. The company will establish a greenfield project, 'Unit 2', involving an investment of USD 150 million to USD 175 million. This facility will house a large-scale mammalian Drug Substance manufacturing unit with a total capacity of 60,000 liters. This move significantly strengthens Aurobindo's footprint in the high-growth biologics CMO sector and deepens its strategic partnership with a global pharmaceutical leader.
முக்கிய அம்சங்கள்
Investment of USD 150 million to USD 175 million for a new greenfield manufacturing facilityInstallation of mammalian cell culture bioreactors with an aggregate capacity of 60,000 liters (60 KL)Expansion of the existing CMO relationship with Merck Sharp & Dohme (MSD) initiated in May 2024Development of 'Unit 2' to include requisite downstream purification infrastructure for Drug Substance production
👀 கவனிக்க வேண்டியவை
Investors should view this as a strategic positive for long-term growth in the high-margin biologics space. Monitor the execution and commissioning timelines of the greenfield project as it represents a significant capital commitment.
Aurobindo Pharma Shareholders Approve Dr. Punita Kumar Sinha as Director with 98.96% Majority
Aurobindo Pharma Limited has announced the successful passage of a special resolution to appoint Dr. (Mrs.) Punita Kumar Sinha as an Independent Director. The resolution was passed via postal ballot with a significant majority of 98.96% of the votes cast in favor. The appointment is for a three-year term effective from February 9, 2026, to February 8, 2029. Total voter participation was high, with 513.4 million votes polled, representing 88.40% of the total equity shares.
முக்கிய அம்சங்கள்
Special resolution for the appointment of Dr. Punita Kumar Sinha passed with 98.96% majority.Total votes polled amounted to 513,445,001, representing 88.40% of the total share capital.The appointment is for a fixed term of 3 consecutive years ending February 8, 2029.Promoter and Promoter Group showed 100% voting participation and unanimous support for the resolution.
👀 கவனிக்க வேண்டியவை
The high level of shareholder consensus for this appointment reflects strong confidence in the company's governance. Investors should view this as a routine but positive reinforcement of the board's independent oversight.
Aurobindo Pharma Subsidiary CuraTeQ Partners with STADA for Biosimilars in EU
CuraTeQ Biologics, a wholly owned subsidiary of Aurobindo Pharma, has entered into a marketing and distribution agreement with STADA Arzneimittel AG. The agreement covers two EMA-approved biosimilars developed by CuraTeQ for select European Union territories, including major markets like France and Germany. This partnership aims to leverage STADA's established distribution network to drive revenue growth and expand market reach for Aurobindo's biosimilar portfolio. Although the company classifies this as a non-material event, it represents a strategic move into the high-value European biologics market.
முக்கிய அம்சங்கள்
Agreement with STADA Arzneimittel AG for marketing and distribution in select EU territories.Focuses on two EMA-approved biosimilars developed by wholly owned subsidiary CuraTeQ Biologics.Target markets include major European economies such as France and Germany.New brand names will be created and registered specifically for each biosimilar product.
👀 கவனிக்க வேண்டியவை
Investors should monitor the commercial launch and revenue ramp-up from these biosimilars as they represent a shift toward higher-margin complex products. This partnership validates the company's R&D capabilities in the biologics space.
Aurobindo Pharma's Unit-V API Facility Receives VAI Status from US FDA; Inspection Closed
Aurobindo Pharma's wholly owned subsidiary, Apitoria Pharma Private Limited, has received an Establishment Inspection Report (EIR) for its Unit-V API manufacturing facility in Telangana. The US FDA has classified the facility as 'Voluntary Action Indicated' (VAI) following an inspection conducted in December 2025. This classification effectively closes the inspection process which had previously resulted in three observations. This development is a positive step in maintaining regulatory compliance for the company's API production and ensures continued supply to the US market.
முக்கிய அம்சங்கள்
US FDA inspected the Unit-V API facility from December 1 to December 12, 2025The inspection initially resulted in a Form 483 with 3 observationsThe facility has now been classified as Voluntary Action Indicated (VAI) by the US FDAThe US FDA has officially closed the inspection for this manufacturing unit
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive development that reduces regulatory uncertainty regarding the company's API supply chain. This clearance supports the company's manufacturing stability and export potential to the US.
Aurobindo Pharma's Eugia Unit-II Classified as OAI by US FDA Following 9 Observations
The US FDA has classified Unit-II of Eugia Pharma Specialities, a wholly-owned subsidiary of Aurobindo Pharma, as 'Official Action Indicated' (OAI). This follows an inspection conducted from November 3 to November 14, 2025, which resulted in 9 observations via Form 483. While the company states it does not foresee an immediate business impact, an OAI status typically delays new product approvals from the facility until regulatory concerns are addressed. Investors should monitor the remediation process closely as this facility is a key part of the company's specialty portfolio.
முக்கிய அம்சங்கள்
US FDA classifies Eugia Pharma Unit-II in Bhiwadi, Rajasthan as 'Official Action Indicated' (OAI)The classification follows an inspection conducted between November 3 and November 14, 2025The inspection originally resulted in the issuance of a Form 483 with 9 specific observationsOAI status may lead to the withholding of new drug approvals (ANDAs) from this specific manufacturing siteManagement currently anticipates no immediate material impact on existing business operations
👀 கவனிக்க வேண்டியவை
Investors should exercise caution as OAI status can escalate to Warning Letters or Import Alerts if remediation is deemed insufficient. Monitor management commentary regarding the timeline for re-inspection and potential delays in the specialty product pipeline.
Aurobindo Pharma Faces ₹77.6 Cr GST Demand and Equal Penalty; To Appeal in GSTAT
Aurobindo Pharma has received an order from the GST Appellate Authority confirming a tax demand of ₹77.61 crore and an equivalent penalty of ₹77.61 crore. The dispute pertains to alleged excess IGST refunds and non-reversal of Input Tax Credit (ITC) for the period between July 2017 and March 2020. While the authority dropped the interest demand on ITC reversal, the primary tax and penalty were upheld. The company has already paid ₹23.72 crore under protest and intends to challenge the ruling at the GST Appellate Tribunal (GSTAT).
முக்கிய அம்சங்கள்
GST demand of ₹77.61 crore confirmed along with a matching penalty of ₹77.61 crore.Issues involve excess IGST refund (CIF vs FOB) and non-reversal of ITC under Rule 37 for FY 2017-2020.Company has already deposited ₹23.72 crore under protest and reversed ₹8.78 crore in ITC.Appellate Authority dropped the demand for interest on ITC reversal while upholding other charges.Aurobindo Pharma plans to file an appeal before the Goods and Services Tax Appellate Tribunal (GSTAT).
👀 கவனிக்க வேண்டியவை
Investors should monitor the outcome of the GSTAT appeal as the total potential liability exceeds ₹150 crore. While the company maintains there is no material impact, persistent tax litigation can weigh on short-term sentiment.
Aurobindo Pharma Subsidiary Unit-IV Receives VAI Status from US FDA
Aurobindo Pharma's wholly owned subsidiary, APL Healthcare Limited, has received an Establishment Inspection Report (EIR) for its Unit-IV facility in Andhra Pradesh. The US FDA has classified the facility as 'Voluntary Action Indicated' (VAI), effectively closing the inspection that took place in December 2025. This follows the initial issuance of a Form 483 with 5 observations at the conclusion of the audit. The VAI classification is a positive outcome, indicating that the regulatory hurdles for this specific unit are resolved for the current cycle.
முக்கிய அம்சங்கள்
US FDA inspected APL Healthcare Unit-IV from December 8 to December 17, 2025The inspection initially resulted in a Form 483 containing 05 observationsFacility has now been classified as Voluntary Action Indicated (VAI) by the US FDAThe receipt of the EIR signifies that the regulatory inspection for this unit is now officially closedUnit-IV is located in SPSR Nellore District, Andhra Pradesh, and is a 100% subsidiary of Aurobindo Pharma
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive development as it clears a regulatory hurdle for a key manufacturing unit. This reduces compliance risk and paves the way for potential new product approvals from this facility.
Aurobindo Pharma Launches Generic Pomalyst in US Targeting $3.3 Billion Market
Aurobindo Pharma's wholly owned subsidiary, Eugia Pharma, has launched Pomalidomide Capsules in the US market. The product is a generic version of BMS Pharmaceuticals' Pomalyst, which has an estimated annual market size of $3.3 billion as of January 2026. As a First-to-File (FTF) applicant, Eugia is well-positioned to capture significant market share in this high-value oncology segment. The product will be manufactured at the company's Eugia Unit-I facility, supporting its specialty portfolio growth.
முக்கிய அம்சங்கள்
Launched Pomalidomide Capsules in 1 mg, 2 mg, 3 mg, and 4 mg strengths in the USTargets a substantial US market size of approximately $3.3 billion according to IQVIA MAT dataEugia Pharma was one of the First-to-File (FTF) ANDA applicants for this productThe product is the generic equivalent of Pomalyst by BMS Pharmaceuticals CorpManufacturing will be handled at the Eugia Unit-I facility
👀 கவனிக்க வேண்டியவை
Investors should monitor the market share gains in the US oncology segment as this launch represents a significant revenue opportunity. The FTF status provides a competitive edge that could bolster margins in the upcoming quarters.
Aurobindo Pharma Director P. Sarath Chandra Reddy Discharged in Delhi Liquor Case
Aurobindo Pharma has confirmed that its Non-Executive Director, Mr. P. Sarath Chandra Reddy, has been discharged by a Special CBI Court in the Delhi Liquor Excise Policy case. The court found no evidence of conspiracy, illegal gratification, or unlawful benefits involving Mr. Reddy after examining material from the CBI's supplementary chargesheet dated July 29, 2024. This discharge applies to all charges leveled by the CBI, effectively removing a significant legal and reputational overhang that had persisted since late 2022. The court specifically noted a lack of basis for including him as an accused in the case.
முக்கிய அம்சங்கள்
Special CBI Court discharged Mr. P. Sarath Chandra Reddy and 22 others on February 27, 2026Court found no material evidence of participation in conspiracy or payment of illegal gratificationMr. Reddy was originally added as Accused No. 23 in a supplementary chargesheet dated July 29, 2024The discharge follows two months of day-to-day arguments and extensive evidence examinationThe court questioned the basis on which Mr. Reddy was arrayed as an accused in the first place
👀 கவனிக்க வேண்டியவை
This is a positive development as it clears a key board member from a high-profile legal controversy, reducing corporate governance concerns. Investors can now focus back on the company's fundamental performance and USFDA compliance status.
Aurobindo Pharma Subsidiary Eugia Unit-I US FDA Inspection Ends with 4 Observations
The US FDA conducted a regulatory inspection at Unit-I of Eugia Pharma Specialities Ltd, a wholly owned subsidiary of Aurobindo Pharma, between February 16 and February 27, 2026. The inspection of this formulation manufacturing facility in Telangana concluded with 4 observations. The company intends to respond to these observations within the stipulated timelines and has stated there is no immediate impact on financials or operations. Investors should monitor the classification of these observations as they can influence future product approvals from this facility.
முக்கிய அம்சங்கள்
US FDA inspection of Eugia Unit-I formulation facility took place from February 16 to February 27, 2026The inspection concluded with 4 observations issued by the regulatory authorityEugia Pharma Specialities Ltd is a 100% wholly owned subsidiary of Aurobindo Pharma LimitedCompany confirms no current quantifiable impact on financials or operations due to the observations
👀 கவனிக்க வேண்டியவை
Investors should wait for the US FDA's final classification of the inspection (NAI, VAI, or OAI) to determine the severity of the 4 observations. While the company claims no immediate impact, any escalation to a Warning Letter could affect the launch pipeline from this unit.
Aurobindo Pharma's wholly owned subsidiary, Eugia Pharma Specialities, has received final USFDA approval for Everolimus Tablets, a generic version of Novartis' Zortress. The approved product is indicated for the prophylaxis of organ rejection in kidney and liver transplant patients. The market size for this medication is estimated at approximately US$ 78 million for the 12 months ending December 2025. This approval marks the 184th ANDA for the Eugia group, with a commercial launch planned for Q1FY27.
முக்கிய அம்சங்கள்
Final USFDA approval for Everolimus Tablets in 0.25 mg, 0.5 mg, 0.75 mg, and 1 mg strengths.Estimated annual market size of US$ 78 million according to IQVIA MAT December 2025 data.Commercial launch is expected to commence in Q1FY27 from the Eugia Unit-I facility.Represents the 184th ANDA approval for the Eugia Pharma Specialities Group.Product is bioequivalent and therapeutically equivalent to the reference drug Zortress by Novartis.
👀 கவனிக்க வேண்டியவை
Investors should monitor the timely launch in Q1FY27 as this adds to Aurobindo's specialty portfolio in the US market. The approval reinforces the company's execution capabilities in the complex generics and specialty segment through its subsidiary Eugia.
Aurobindo Pharma Incorporates New Subsidiary Engenra Biologics for CDMO Expansion
Aurobindo Pharma has incorporated a new wholly-owned subsidiary, Engenra Biologics Private Limited, in India on February 24, 2026. The subsidiary is established with an initial cash subscription of Rs. 10 lakhs, representing 1,00,000 equity shares at Rs. 10 each. The primary objective of this new entity is to expand the company's contract manufacturing (CDMO) and other pharmaceutical manufacturing operations. This move signals Aurobindo's intent to scale its specialized manufacturing capabilities within the domestic market.
முக்கிய அம்சங்கள்
Incorporation of Engenra Biologics Private Limited as a 100% wholly-owned subsidiaryInitial capital investment of Rs. 10 lakhs divided into 1,00,000 equity sharesStrategic focus on expanding contract manufacturing and pharmaceutical operationsEntity incorporated in India with 100% control and no prior turnover historyTransaction conducted at arms-length with no promoter group interest
👀 கவனிக்க வேண்டியவை
Investors should monitor the scale of capital expenditure and future contract wins under this new subsidiary as it indicates Aurobindo's growth trajectory in the CDMO space. The stock remains a watch for long-term expansion in specialized manufacturing.
Aurobindo Pharma Receives ₹169.84 Crore GST Demand and Penalty Order
Aurobindo Pharma has been served with four orders from the GST Department demanding the recovery of ₹169.84 crores in previously granted refunds. The demand includes ₹84.92 crores in GST and an equivalent penalty of ₹84.92 crores for the period of September to December 2022. The dispute involves the calculation of Input Tax Credit (ITC) refunds for its EOU Unit 3, which the department alleges were erroneous. The company intends to contest this demand through an appeal, stating that there is no material impact on its current operations.
முக்கிய அம்சங்கள்
Total disputed amount stands at ₹169.84 crores, including a 100% penalty of ₹84.92 crores.The orders allege erroneous refund of accumulated ITC under Rule 89 of CGST Rules for late 2022.The dispute centers on whether domestic market values of similar goods should limit export refund amounts.Aurobindo Pharma is challenging the validity of Rule 89(4)(C) in the Telangana High Court.The company will file a fresh appeal before the Commissioner of Central Tax (Appeals), Hyderabad.
👀 கவனிக்க வேண்டியவை
Investors should monitor the legal proceedings as tax disputes are common in the sector; however, the immediate financial impact is limited given the company's scale. No immediate action is required as the company is actively contesting the demand.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
